Akcea therapeutics, inc. (AKCA)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Sep'16Jun'16
Revenue:
Revenue

340,801

488,543

221,260

219,877

211,575

64,867

76,358

67,023

54,415

43,401

0

0

0

-

-

Research and development revenue under collaborative agreements

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Expenses:
Cost of sales - intangible asset amortization

5,706

5,690

6,268

5,535

0

0

0

-

-

-

-

-

-

-

-

Research and development

210,588

292,852

178,219

182,803

201,989

130,340

122,776

111,035

90,065

126,889

117,926

111,230

0

0

0

Selling, general and administrative

183,325

181,681

176,181

187,200

178,747

153,610

124,694

87,143

51,771

36,982

22,861

17,250

0

0

0

Total expenses

374,193

450,469

338,407

369,442

385,857

295,683

256,414

198,178

141,836

163,871

140,787

128,480

0

0

0

(Loss) income from operations

-33,392

38,074

-117,147

-149,565

-174,282

-230,816

-180,056

-131,155

-87,421

-120,470

-119,074

-116,673

0

0

0

Other income (expense):
Investment income

6,052

5,505

5,824

6,012

5,987

5,631

4,908

3,920

2,619

1,812

1,086

490

0

0

0

Interest expense

-

-

-

-

-

-

-

-

-

1,731

1,730

1,506

0

0

0

Other expense

-633

-615

-317

-206

-133

-189

-167

-69

-64

0

0

0

-

-

-

(Loss) income before income tax expense

-27,973

42,964

-111,640

-143,759

-168,428

-225,374

-175,315

-127,528

-86,055

-120,284

-119,595

0

0

0

-

Income tax benefit (expense)

1,292

2,192

784

739

0

-

0

0

-

0

0

-

-

0

-

Net (loss) income

-29,265

40,772

-112,191

-144,284

-169,007

-225,821

-174,971

-129,017

-87,330

-121,559

-121,661

-117,639

0

0

0

Net loss per share, basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.47

Weighted-average shares outstanding, basic and diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28,884

Weighted-average shares of common stock outstanding, diluted

-

-

-

-

94,127

-

-

-

-

-

-

-

-

-

-

Product [Member]
Revenue

50,658

42,253

30,800

0

0

0

-

-

-

-

-

-

-

-

-

Cost of sales

6,892

4,569

4,149

4,225

0

0

0

-

-

-

-

-

-

-

-

Research and Development and License Revenue Under Collaborative Agreement [Member]
Revenue

279,971

436,118

184,288

182,985

190,584

50,630

64,358

67,023

54,415

43,401

0

0

0

-

-

Commercial Revenue [Member]
Revenue

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

Licensing [Member]
Revenue

-

0

0

0

-

-

0

-

-

-

-

-

-

-

-

Cost of product/license

-

0

-

0

-

-

0

-

-

-

-

-

-

-

-

Ionis [Member]
Net loss share from commercial activities under arrangement with Ionis Pharmaceuticals, Inc.

37,718

39,723

0

0

0

-

-

-

-

-

-

-

-

-

-

Preferred Stock [Member]
Net income (loss)

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net loss per share, basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

1.12

-0.01

-0.70

-2.21

-

-

Weighted-average shares outstanding, basic and diluted (in shares)

-

-

-

-

-

-

-

-

-

-432

5,651

28,888

28,884

-

-

Common Stock [Member]
Net loss

-

-

-

-

-

-

-

0

-

-

0

-

-

-

-

Weighted-average shares of common stock outstanding, basic

101,105

-

-

-

90,708

-

-

-

66,619

-

-

-

-

-

-